GlassScriptPhysician profile
Dhiren Patel
NPI 1437644515
$2,054.50
in general payments reported to CMS, 2019-2025
29 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $190 · 2021: $227 · 2022: $236 · 2023: $540 · 2024: $534 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.06 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $340.13 | 2022-2025 | Wakix |
| Inspire Medical Systems, INC. | $244.80 | 2023 | Inspire |
| Celgene Corporation | $244.04 | 2023-2025 | Zeposia |
| Greenwich Biosciences, INC. | $190.71 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $149.93 | 2022-2023 | |
| Depuy Synthes Sales INC. | $105.63 | 2020 | |
| Ucb, INC. | $93.46 | 2019-2025 | Briviact |
| Eisai INC. | $81.53 | 2020-2025 | |
| Abbvie INC. | $78.52 | 2024-2025 | |
| Allergan, INC. | $44.60 | 2021 | |
| Merz Pharmaceuticals, LLC | $40.47 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Alexion Pharmaceuticals, INC. | $39.59 | 2019-2021 | |
| Averitas Pharma INC. | $38.84 | 2024 | Qutenza |
| Avadel Cns Pharmaceuticals, LLC | $36.44 | 2024 | Lumryz |
| Livanova USA, INC. | $35.96 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $35.20 | 2021 | |
| Sk Life Science, INC. | $34.11 | 2021-2023 | |
| Baxter Healthcare | $26.12 | 2024 | Perclot |
| Acadia Pharmaceuticals INC | $25.06 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Akcea Therapeutics, INC. | $19.75 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.42 | 2022 | |
| Optinose US, INC. | $17.40 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.39 | 2022 | |
| Pfizer INC. | $16.37 | 2019 | |
| Axsome Therapeutics, INC. | $16.03 | 2023 | Sunosi |
| Lilly USA, LLC | $15.97 | 2025 | Kisunla |
| Resmed Corp | $14.93 | 2023 | |
| Genzyme Corporation | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhiren Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.